Search

Your search keyword '"Morgenstern, Alfred"' showing total 866 results
Start Over Author "Morgenstern, Alfred"
866 results on '"Morgenstern, Alfred"'

5. Nuclear education and training activities of the Joint Research Centre of the European Commission: Maintaining and enhancing nuclear skills and competences

Author

Michailidou, Eirini, Martin Ramos, Manuel, Galy, Jean, Eriksen, Brian, Eriksson, Arne, Goulart, Margarida, Janssens, Willem, Berthou, Veronique, Eloirdi, Rachel, Morgenstern, Alfred, Kellerbauer, Alban, Van Uffelen, Paul, Seibert, Alice, Mayer, Klaus, Bagi, Janos, Raison, Philippe, Aregbe, Yetunde, Schillebeeckx, Peter, Wastin, Franck, and Piagentini, Andrea

Published
2024
Full Text
View/download PDF

11. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study

Author

Sathekge, Mike M, Lawal, Ismaheel O, Bal, Chandrasekhar, Bruchertseifer, Frank, Ballal, Sajana, Cardaci, Giuseppe, Davis, Cindy, Eiber, Mathias, Hekimsoy, Türkay, Knoesen, Otto, Kratochwil, Clemens, Lenzo, Nat P, Mahapane, Johncy, Maserumule, Letjie C, Mdlophane, Amanda H, Mokoala, Kgomotso M G, Ndlovu, Honest, Pant, Vineet, Rathke, Hendrik, Reed, Janet, Sen, Ishita B, Singh, Aviral, Sood, Ashwani, Tauber, Robert, Thakral, Parul, Yadav, Madhav Prasad, and Morgenstern, Alfred

Published
2024
Full Text
View/download PDF

15. Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 α-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer

Author

Lawal, Ismaheel O., Morgenstern, Alfred, Vorster, Mariza, Knoesen, Otto, Mahapane, Johncy, Hlongwa, Khanyisile N., Maserumule, Letjie C., Ndlovu, Honest, Reed, Janet D., Popoola, Gbenga O., Mokoala, Kgomotso M. G., Mdlophane, Amanda, Bruchertseifer, Frank, and Sathekge, Mike M.

Published
2022
Full Text
View/download PDF

17. Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer

Author

Privé, Bastiaan M., Slootbeek, Peter H. J., Laarhuis, Babette I., Naga, Samhita Pamidimarri, van der Doelen, Maarten J., van Kalmthout, Ludwike W. M., de Keizer, Bart, Ezziddin, Samer, Kratochwil, Clemens, Morgenstern, Alfred, Bruchertseifer, Frank, Ligtenberg, Marjolijn J. L., Witjes, J. Alfred, van Oort, Inge M., Gotthardt, Martin, Heskamp, Sandra, Janssen, Marcel J. R., Gerritsen, Winald R., Nagarajah, James, and Mehra, Niven

Published
2022
Full Text
View/download PDF

23. Comparative Analysis of Morphological and Functional Effects of 225Ac- and 177Lu-PSMA Radioligand Therapies (RLTs) on Salivary Glands

Author

Feuerecker, Benedikt, primary, Gafita, Andrei, additional, Langbein, Thomas, additional, Tauber, Robert, additional, Seidl, Christof, additional, Bruchertseifer, Frank, additional, Gschwendt, Jürgen E., additional, Weber, Wolfgang A., additional, D’Alessandria, Calogero, additional, Morgenstern, Alfred, additional, and Eiber, Matthias, additional

Published
2023
Full Text
View/download PDF

24. Molecular Radiation Resistance Signature Induced by Alpha Emitters in Metastatic Castration-resistant Prostate Cancer: Early Clinical Outcome Prediction

Author

Amghar, Mariam, primary, Hielscher, Thomas, additional, Bauder-Wuest, Ulrike, additional, Roscher, Mareike, additional, Schick, Matthias, additional, Bakos, Gábor, additional, Remde, Yvonne, additional, Schaefer, Martin, additional, Bruchertseifer, Frank, additional, Morgenstern, Alfred, additional, Kratochwil, Clemens, additional, and Benešová-Schäfer, Martina, additional

Published
2023
Full Text
View/download PDF

30. Locoregional Treatment of Brain Tumors

Author

Kunikowska, Jolanta, Morgenstern, Alfred, Bruchertseifer, Frank, Krolicki, Leszek, Bombardieri, Emilio, editor, Seregni, Ettore, editor, Evangelista, Laura, editor, Chiesa, Carlo, editor, and Chiti, Arturo, editor

Published
2018
Full Text
View/download PDF

31. Targeted α-Therapy Using225Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment

Author

Ertveldt, Thomas, Krasniqi, Ahmet, Ceuppens, Hannelore, Puttemans, Janik, Dekempeneer, Yana, De Jonghe, Kevin, De Mey, Wout, Lecocq, Quentin, De Vlaeminck, Yannick, Awad, Robin Maximilian, Goyvaerts, Cleo, De Veirman, Kim, Morgenstern, Alfred, Bruchertseifer, Frank, Keyaerts, Marleen, Devoogdt, Nick, D'Huyvetter, Matthias, Breckpot, Karine, Brussels Heritage Lab, Laboratory of Molecullar and Cellular Therapy, Basic (bio-) Medical Sciences, Faculty of Medicine and Pharmacy, Medical Imaging, Clinical sciences, Supporting clinical sciences, Hematology, and Nuclear Medicine

Subjects
hematology, Radiology Nuclear Medicine and imaging, Immunology and Microbiology(all), Immunology, oncology, Radionuclide Therapy, Radiology, Nuclear Medicine and imaging, actinium-225, single-domain antibody
Abstract

Targeted radionuclide therapy (TRT) using targeting moieties labeled with α-particle-emitting radionuclides (α-TRT) is an intensely investigated treatment approach as the short range of α-particles allows effective treatment of local lesions and micrometastases. However, profound assessment of the immunomodulatory effect of α-TRT is lacking in literature. Methods: Using flow cytometry of tumors, splenocyte restimulation, and multiplex analysis of blood serum, we studied immunologic responses ensuing from TRT with an antihuman CD20 single-domain antibody radiolabeled with 225Ac in a human CD20 and ovalbumin expressing B16-melanoma model. Results: Tumor growth was delayed with α-TRT and increased blood levels of various cytokines such as interferon-γ, C-C motif chemokine ligand 5, granulocyte-macrophage colony-stimulating factor, and monocyte chemoattractant protein-1. Peripheral antitumoral T-cell responses were detected on α-TRT. At the tumor site, α-TRT modulated the cold tumor microenvironment (TME) to a more hospitable and hot habitat for antitumoral immune cells, characterized by a decrease in protumoral alternatively activated macrophages and an increase in antitumoral macrophages and dendritic cells. We also showed that α-TRT increased the percentage of programmed death-ligand 1 (PD-L1)-positive (PD-L1pos) immune cells in the TME. To circumvent this immunosuppressive countermeasure we applied immune checkpoint blockade of the programmed cell death protein 1-PD-L1 axis. Combination of α-TRT with PD-L1 blockade potentiated the therapeutic effect, however, the combination aggravated adverse events. A long-term toxicity study revealed severe kidney damage ensuing from α-TRT. Conclusion: These data suggest that α-TRT alters the TME and induces systemic antitumoral immune responses, which explains why immune checkpoint blockade enhances the therapeutic effect of α-TRT. However, further optimization is warranted to avoid adverse events.

Published
2023

32. Evaluation of the tolerability and safety of [225Ac]Ac-PSMA-I&T in patients with metastatic prostate cancer: a phase I dose escalation study.

Author

Ling, Sui wai, van der Veldt, Astrid A. M., Konijnenberg, Mark, Segbers, Marcel, Hooijman, Eline, Bruchertseifer, Frank, Morgenstern, Alfred, de Blois, Erik, and Brabander, Tessa

Subjects
PROSTATE cancer, PROSTATE cancer patients, CASTRATION-resistant prostate cancer, LINEAR energy transfer
Abstract

Background: Life expectancy of patients with metastatic castration-resistant prostate cancer (mCRPC) is still limited despite several systemic treatments. Within five years after diagnosis of primary prostate cancer, 10–20% of the patients have mCRPC and curation is not an option. Radionuclide therapy (RNT) targeted against prostate-specific membrane antigen (PSMA) emerged as a new treatment option and showed effective results in patients with mCRPC. Survival benefit after [177Lu]Lu-PSMA RNT has already been demonstrated in several clinical trials. However, [225Ac]Ac-PSMA (225Ac-PSMA) appears to be an even more promising radiopharmaceutical for the treatment of mCRPC. The use of alpha emitting radionuclides offers advantages over beta emitting radionuclides due to the high linear energy transfer effective for killing tumor cells and the limited range to reduce the radiation effects on the healthy tissue. However, these results are based on retrospective data and safety data of 225Ac-PSMA are still limited. Therefore, a prospective trial is needed to determine the optimal amount of activity that can be administered. Methods: The 225Ac-PSMA-Imaging & Therapy (I&T) trial is an investigator-initiated phase I, single-center, open label, repeated dose-escalation and expansion trial. Patient with PSMA-positive mCRPC after at least one line of chemotherapy and/or one line of nonsteroidal antiandrogen will be treated with 225Ac-PSMA-I&T in increasing amount of activity per cycle. Dose-escalation following an accelerated 3 + 3 design which allows to open the next dose-level cohort in the absence of dose limiting toxicity while the previous one is still ongoing. Up to 4 treatment cohorts will be explored including up to 3 dose-escalation cohorts and one expansion cohort where patients will be administered with the recommended dose. A total of up to 30 patients will be enrolled in this trial. All patients will be evaluated for safety. Additionally, dosimetry was performed for the patients in the dose-escalation cohorts after the first 225Ac-PSMA-I&T administration. Discussion: This trial will assess the safety and tolerability of 225Ac-PSMA-I&T in patients with mCRPC to recommend the optimal dose for the phase II trial. Trial registration: ClinicalTrials.gov, (NCT05902247). Retrospectively registered 13 June 2023. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

33. Comparative Analysis of Morphological and Functional Effects of 225 Ac- and 177 Lu-PSMA Radioligand Therapies (RLTs) on Salivary Glands.

Author

Feuerecker, Benedikt, Gafita, Andrei, Langbein, Thomas, Tauber, Robert, Seidl, Christof, Bruchertseifer, Frank, Gschwendt, Jürgen E., Weber, Wolfgang A., D'Alessandria, Calogero, Morgenstern, Alfred, and Eiber, Matthias

Subjects
SALIVARY glands, FUNCTIONAL analysis, COMPARATIVE studies, SMALL molecules, LUTETIUM compounds
Abstract

Most Prostate Specific Membrane Antigens (PSMAs) targeting small molecules accumulate in the salivary glands (SGs), raising concerns about SG toxicity, especially after repeated therapies or therapy with 225Ac-labeled ligands. SG toxicity is assessed clinically by the severity of patient-reported xerostomia, but this parameter can be challenging to objectively quantify. Therefore, we explored the feasibility of using SG volume as a biomarker for toxicity. In 21 patients with late-stage metastatic resistant prostate cancer (mCRPC), the PSMA volume and ligand uptake of SG were analyzed retrospectively before and after two cycles of 177Lu-PSMA (LuPSMA; cohort A) and before and after one cycle of 225Ac-PSMA-617 (AcPSMA, cohort B). Mean Volume-SG in cohort A was 59 ± 13 vs. 54 ± 16 mL (−10%, p = 0.4), and in cohort B, it was 50 ± 13 vs. 40 ± 11 mL (−20%, p = 0.007), respectively. A statistically significant decrease in the activity concentration in the SG was only observed in group B (SUVmean: 9.2 ± 2.8 vs. 5.3 ± 1.8, p < 0.0001; vs. A: SUVmean: 11.2 ± 3.3 vs. 11.1 ± 3.5, p = 0.8). SG volume and PSMA-ligand uptake are promising markers to monitor the SG toxicity after a PSMA RLT. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

40. Supplementary Data from Preclinical Evaluation of 225Ac-Labeled Single-Domain Antibody for the Treatment of HER2pos Cancer

Author

Rodak, Magdalena, primary, Dekempeneer, Yana, primary, Wojewódzka, Maria, primary, Caveliers, Vicky, primary, Covens, Peter, primary, Miller, Brian W., primary, Sevenois, Matthijs B., primary, Bruchertseifer, Frank, primary, Morgenstern, Alfred, primary, Lahoutte, Tony, primary, D'Huyvetter, Matthias, primary, and Pruszyński, Marek, primary

Published
2023
Full Text
View/download PDF

41. Data from Preclinical Evaluation of 225Ac-Labeled Single-Domain Antibody for the Treatment of HER2pos Cancer

Author

Rodak, Magdalena, primary, Dekempeneer, Yana, primary, Wojewódzka, Maria, primary, Caveliers, Vicky, primary, Covens, Peter, primary, Miller, Brian W., primary, Sevenois, Matthijs B., primary, Bruchertseifer, Frank, primary, Morgenstern, Alfred, primary, Lahoutte, Tony, primary, D'Huyvetter, Matthias, primary, and Pruszyński, Marek, primary

Published
2023
Full Text
View/download PDF

45. Figure S4 from Drugs That Modify Cholesterol Metabolism Alter the p38/JNK-Mediated Targeted and Nontargeted Response to Alpha and Auger Radioimmunotherapy

Author

Ladjohounlou, Riad, primary, Lozza, Catherine, primary, Pichard, Alexandre, primary, Constanzo, Julie, primary, Karam, Jihad, primary, Le Fur, Pierre, primary, Deshayes, Emmanuel, primary, Boudousq, Vincent, primary, Paillas, Salomé, primary, Busson, Muriel, primary, Le Blay, Marion, primary, Jarlier, Marta, primary, Marcatili, Sara, primary, Bardiès, Manuel, primary, Bruchertseifer, Frank, primary, Morgenstern, Alfred, primary, Torgue, Julien, primary, Navarro-Teulon, Isabelle, primary, and Pouget, Jean-Pierre, primary

Published
2023
Full Text
View/download PDF

46. Supplementary Data from Drugs That Modify Cholesterol Metabolism Alter the p38/JNK-Mediated Targeted and Nontargeted Response to Alpha and Auger Radioimmunotherapy

Author

Ladjohounlou, Riad, primary, Lozza, Catherine, primary, Pichard, Alexandre, primary, Constanzo, Julie, primary, Karam, Jihad, primary, Le Fur, Pierre, primary, Deshayes, Emmanuel, primary, Boudousq, Vincent, primary, Paillas, Salomé, primary, Busson, Muriel, primary, Le Blay, Marion, primary, Jarlier, Marta, primary, Marcatili, Sara, primary, Bardiès, Manuel, primary, Bruchertseifer, Frank, primary, Morgenstern, Alfred, primary, Torgue, Julien, primary, Navarro-Teulon, Isabelle, primary, and Pouget, Jean-Pierre, primary

Published
2023
Full Text
View/download PDF

47. Data from Drugs That Modify Cholesterol Metabolism Alter the p38/JNK-Mediated Targeted and Nontargeted Response to Alpha and Auger Radioimmunotherapy

Author

Ladjohounlou, Riad, primary, Lozza, Catherine, primary, Pichard, Alexandre, primary, Constanzo, Julie, primary, Karam, Jihad, primary, Le Fur, Pierre, primary, Deshayes, Emmanuel, primary, Boudousq, Vincent, primary, Paillas, Salomé, primary, Busson, Muriel, primary, Le Blay, Marion, primary, Jarlier, Marta, primary, Marcatili, Sara, primary, Bardiès, Manuel, primary, Bruchertseifer, Frank, primary, Morgenstern, Alfred, primary, Torgue, Julien, primary, Navarro-Teulon, Isabelle, primary, and Pouget, Jean-Pierre, primary

Published
2023
Full Text
View/download PDF

50. Supplementary Data from The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide Therapy

Author

Puttemans, Janik, primary, Stijlemans, Benoit, primary, Keyaerts, Marleen, primary, Vander Meeren, Sam, primary, Renmans, Wim, primary, Fostier, Karel, primary, Debie, Pieterjan, primary, Hanssens, Heleen, primary, Rodak, Magdalena, primary, Pruszynski, Marek, primary, De Veirman, Kim, primary, Vanderkerken, Karin, primary, Lahoutte, Tony, primary, Morgenstern, Alfred, primary, Bruchertseifer, Frank, primary, Devoogdt, Nick, primary, and D'Huyvetter, Matthias, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results